EUCTR2011-004755-39-IE进行中（未招募）1 期
A randomized phase II study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer - MAVERICC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Disease-specific inclusion criteria
- •1. Histologically or cytologically confirmed CRC with at least one
- •measurable metastatic lesion by RECIST, v1.1. (Baseline tumor assessments must be done within 28 days prior to randomization)
- •2. Archival tumor tissue sample (i.e., representative tumor tissue specimen in paraffin block [preferred] or at least 22 unstained slides) must be requested and available prior to study entry. If no archival tumor tissue sample is available, a fresh biopsy tissue sample must be obtained but should be discussed first with the medical monitor. A copy of the local pathology report must be submitted along with the specimens
- •b. General inclusion criteria
- •3. Signed informed consent prior to initiation of any study-specific procedure or treatment
- •4. Age >= 18 years
- •5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •6. Able to comply with the protocol, including tissue and blood sampling
- •7. Adequate hematological function:
- •Absolute neutrophil count >= 1500 per mm3 AND
- •Platelet count >= 100,000 per mm3 AND
- •Hemoglobin >= 9 g/dL (may be transfused to maintain or exceed this level)
- •8. Adequate liver function:
- •Total bilirubin < 1.5 x upper limit of normal (ULN) AND
- •Aspartate aminotransferase and alanine aminotransferase < 2.5 x ULN in patients without liver metastases or < 5 x ULN in patients with liver metastases
- •9. Adequate renal function:
- •Calculated creatinine clearance according to the formula of Cockroft and Gault >= 50 mL/min AND
- •Urine for proteinuria should be < 2 +. Patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours
- •10. International normalized ratio <= 1.5 and activated prothrombin time <= 1.5 x ULN for patients not receiving anti-coagulation therapy. The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
- •11. Patients with treated brain metastases are eligible for study participation. Patients may not receive ongoing treatment with steroids at screening. Anticonvulsants (at stable dose) are allowed. Treatment for brain metastases may be whole-brain radiotherapy, radiosurgery, neurosurgery, or a combination as deemed appropriate by the treating physician. Radiotherapy and stereotactic radiosurgery must be completed at least 28 days prior to randomization
- •12. Female patients should not be pregnant or breast-feeding. Female patients with childbearing potential should agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least 6 months following the last administration of study drugs. Female patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the study
- •13. Male patients must agree to use effective contraception during the study and for a period of at least 6 months following the last administration of study drugs, even if they have been surgically sterilized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age
排除标准
- •a. Disease-specific exclusions
- •1. Any prior systemic treatment for metastatic CRC
- •2. Adjuvant chemotherapy for CRC completed < 12 months
- •3. Sensory peripheral neuropathy >= grade 2
- •4. Evidence of Gilbert’s Syndrome or of homozygosity for the UGT1A1*28 allele.
- •-Patients with Gilbert’s Syndrome may have a greater risk of irinotecan toxicity due to the abnormal glucuronidation of SN-38. Evidence of Gilbert’s Syndrome would include a prior finding of an isolated elevation of indirect bilirubin. UGT1A1 genotyping is not required on this study
- •5. Known positivity for human immunodeficiency virus (HIV)
- •b. General medical exclusions
- •6. Malignancies other than metastatic CRC within 5 years prior to
- •randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
- •7. Radiotherapy to any site for any reason within 28 days prior to
- •randomization, except for palliative radiotherapy to bone lesions within 14 days prior to randomization
- •8. Clinically detectable (by physical exam) third-space fluid collections (e.g., ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entry
- •9. Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
- •c. Bevacizumab-specific exclusions
- •10. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of bevacizumab or puts the patient at high risk for treatment-related complications
- •11. Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during study treatment
- •12. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion
- •13. Current or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (> 325 mg/day). Prophylactic and therapeutic use of anticoagulants is allowed, e.g., warfarin (1 mg QD) for catheter prophylaxis, and prophylactic low molecular-weight heparin (i.e., enoxaparin [40 mg QD]). Current or recent (within 10 days prior to first dose of bevacizumab) use of full dose (i.e., therapeutic dose) of thrombolytic agents for therapeutic purposes
- •14. History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
- •15. Inadequately controlled hypertension (blood pressure: systolic > 150 mmHg and/or diastolic > 100 mmHg)
- •16. Clinically significant (i.e., active) cardiovascular disease (e.g.,
- •cerebrovascular accident or myocardial infarction within 6 months prior to randomization), unstable angina, congestive heart failure (New York Heart Association Class >= II,) or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with administration of study treatment
- •17. Serious non-healing wound, active peptic ulcer, or untreated bone fracture
- •18. History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months of randomization
- •19. Known hypersensitivity to bevacizumab or any of its excipients or any other study drug
研究者
相似试验
进行中（未招募）
不适用
Marker Evaluation for Avastin Research in colorectal cancerEUCTR2011-004755-39-EEGenentech, Inc.360
进行中（未招募）
1 期
Marker Evaluation for Avastin Research in colorectal cancerMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004755-39-PTGenentech, Inc.360
招募中
2 期
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancerower rectal cancerJPRN-UMIN000031028Kobe University Graduate School of Medicine40
招募中
2 期
Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11Metastatic colorectal cancerJPRN-UMIN000006911Tsuchiura kyodo general hospital60
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45